The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone
| Autor: | Ryuta Shintakuya, Keisuke Okano, Naru Kondo, Taijiro Sueda, Shinya Takahashi, Kenichiro Uemura, Naoya Nakagawa, Yoshiaki Murakami |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_specialty Stromal cell Pancreatic ductal adenocarcinoma Endocrinology Diabetes and Metabolism medicine.medical_treatment Antineoplastic Agents Deoxycytidine 03 medical and health sciences 0302 clinical medicine Borderline resectable Internal medicine Pancreatic cancer Humans Medicine Osteonectin In patient Aged Retrospective Studies Tegafur Hepatology business.industry Gastroenterology medicine.disease Survival Analysis Gemcitabine Gene Expression Regulation Neoplastic Drug Combinations Oxonic Acid 030220 oncology & carcinogenesis Biomarker (medicine) Female 030211 gastroenterology & hepatology business Adjuvant Carcinoma Pancreatic Ductal medicine.drug |
| Zdroj: | Pancreatology. 18:191-197 |
| ISSN: | 1424-3903 |
| Popis: | Although postoperative adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC) improves survival, its efficacy varies among individuals. Identification of biomarkers that can predict the efficacy of adjuvant chemotherapy for PDAC is essential.To investigate the predictive value of secreted protein acidic and rich in cysteine (SPARC) expression in patients with PDAC treated with adjuvant gemcitabine in combination with S-1 (adjuvant GS) or adjuvant gemcitabine alone (adjuvant G alone).Stromal SPARC and cytoplasmic SPARC were examined immunohistochemically in 211 PDAC patients treated with adjuvant GS or G alone after resection. The association of SPARC expression with clinicopathological factors, disease-free survival (DFS) and overall survival (OS) were analyzed.In multivariate analysis, borderline resectable with arterial contact (BR-A) (P = .002), higher preoperative CA 19-9 level (≥91 U/ml) (P = .005), moderately or poorly (P = .003), presence of lymph node metastasis (P = .012) and high stromal SPARC expression (P = .013) were independent predictors of poor DFS. Moreover, BR-A (P = .003), higher preoperative CA 19-9 level (≥91 U/ml) (P = .007) and high stromal SPARC expression (P .001) were identified as independent predictors of poor OS. In contrast, cytoplasmic SPARC expression did not affect DFS and OS.High stromal SPARC expression was an independent predictor of poor DFS and OS in patients treated with adjuvant GS or G alone. Stromal SPARC expression could be a relevant biomarker for prediction of prognosis in PDAC patients after resection treated with adjuvant GS or G alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect